

# *Promotional Submissions in eCTD Format - Grouped Submissions*

**Jason Cober**

*Lead Project Manager*

Office of Prescription Drug Promotion (OPDP)

CDER | US FDA

# Outline



- Background
- eCTD Structure
- Contents of a Grouped Submission
- Common Errors

# Background



- June 24, 2019 – FDA Published Final Guidance titled *“Providing Regulatory Submissions in Electronic and Non-Electronic Format – Promotional Labeling and Advertising Materials for Human Prescription Drugs”*
- Guidance describes the structure and format for promotional submissions in eCTD format
- Grouped Submissions are discussed in Section VI.J of the guidance

# How does a grouped submission work?



- The contents of the grouped submission are distributed to all member Applications included in the group
- A record is created under each Application in the group
  - Sequence Number submitted in US-Regional file is used to create the submission record
  - A link to the shared location of the submission contents are added to each record
- Reviewer sees one submission linked to multiple Applications

# What is a Grouped Submission?



- Single submission in eCTD format
- Contains promotional materials that promote more than one Product
- Contains the current labeling for each promoted Product
  - Can contain draft labeling when submitted for Accelerated Approval or Advisory
- Promoted products must be of the same Application Type
  - If the promoted products are not the same Application Type, the materials must be submitted separately
    - Either a Single-Product Submissions or grouped submissions batched by Application Type

# Technical Considerations



- US-Regional.xml file must include all member Applications in the Application Set section
- Each member Application must include a Sequence Number
  - Must be unique to the respective Application
  - Must not have been previously submitted under its respective Application
  - If any grouped submission includes an Application Number and Sequence Number combination that has been previously submitted, the entire group will be rejected

# Technical Considerations



- <Application-Set> section may contain one or multiple <Application> elements
- The <Application-Containing-Files> attribute is used to indicate the Lead Application
  - <Application-Containing-Files> = True is the Lead
  - <Application-Containing-Files> = False are non-Lead Member(s)
- Lead Application should be listed first in the Application Section
- Grouped Submission may only contain one Lead Application

# Example



Application Information	
	<p>Application Containing Files: true</p> <p>Application Type: New Drug Application (NDA)</p> <p>Application Number: 456789</p> <p><del>Submission Type: Promotional Labeling Advertising</del></p> <p>Submission Id: 0017</p> <p>Submission Sub-Type: Original</p> <p>Sequence #: 0017</p>
	<p>Application Containing Files: false</p> <p>Application Type: New Drug Application (NDA)</p> <p>Application Number: 567890</p> <p><del>Submission Type: Promotional Labeling Advertising</del></p> <p>Submission Id: 0020</p> <p>Submission Sub-Type: Original</p> <p>Sequence #: 0020</p>
	<p>Application Containing Files: false</p> <p>Application Type: New Drug Application (NDA)</p> <p>Application Number: 678901</p> <p><del>Submission Type: Promotional Labeling Advertising</del></p> <p>Submission Id: 0014</p> <p>Submission Sub-Type: Original</p> <p>Sequence #: 0014</p>





# Grouped Submission Contents

# 2253 Grouped Submissions



- Same required submission contents as a Single-Product 2253
  - Completed Form FDA 2253
  - Current PI for all members of the group
  - Clean copy of Promotional Material(s)

# Form FDA 2253



- The Application listed as the Lead Application in the US-Regional.xml file should match the Application Listed on the Form FDA 2253
- Form FDA 2253 should indicate it is a Multi-Product Submission
- Non-Lead members should be listed on a separate Supplemental Application List
  - Supplemental Application List should include
    - Application Type & Number
    - Product Name
    - Date and File Name of Current PI
- Supplemental Application list should be submitted in the same section as the completed Form FDA 2253

# Example



m1-1-forms

Form FDA 2253: Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use

Form 2253 Multiple Product Prof 20120430 [new]

+  
-  
Application Version =  
Checksum = 49e154b9bee094a2dm83c459affd63e4  
Checksum Type = md5  
Filename = 2253-20120430.pdf  
Font Library =  
ID = a11383b1215558nfd8a81em95237f796  
Keywords =  
Operation = new  
Version =

Form 2253 Attachment List of Additional Applications [new]

+  
-  
Application Version =  
Checksum = 49e154b9bee094a2dm83c459affd63e4  
Checksum Type = md5  
Filename = form\_attachment.pdf  
Font Library =  
ID = a11389b1215558nfd8a81em95237f796  
Keywords =  
Operation = new  
Version =

# 2253 Labeling



- Grouped 2253 must be accompanied by Current Product Labeling for each member of the group
- Labeling must be placed under Heading 1.14.6
- Submitters may submit a separate PDF copy of each Label under 1.14.6
- Alternately, if the Current Product Label has been submitted previously, a cross-reference to the Product Labeling may be used

# Example



## m1-14-6-product-labeling-for-2253-submissions

acetyl salicylic acid PI Rev20120130 [new]  
+  
-  
Application Version =  
Checksum = 49e154b9nww061v8de43c459affd53e4  
Checksum Type = md5  
Filename = labeling-accompanying-material.pdf  
Font Library =  
ID = a11383x9845892nfd8a81em95237f796  
Keywords =  
Operation = new  
Version =

Drug X PI Rev20120215 [new]  
+  
-  
Application Version =  
Checksum = 49e154b9nww061v8de43c459affd63e4  
Checksum Type = md5  
Filename = labeling-accompanying-material-drug-x.pdf  
Font Library =  
ID = a11384x9845892nfd8a81em95237f796  
Keywords =  
Operation = new  
Version =

Drug Z PI Rev20120220 [new]  
+  
-  
Application Version =  
Checksum = 49e154b9nww061v8de43c459affd65e4  
Checksum Type = md5  
Filename = labeling-accompanying-material-drug-z.pdf  
Font Library =  
ID = a11389x9845892nfd8a81em95237f796  
Keywords =  
Operation = new  
Version =

# 2253 Materials



- Only include one set of materials under section 1.15.2
- Each material included in the group will be linked to all members of the group

# Example



m1-15-promotional-material (Professional)

m1-15-2-materials (Promotional 2253)

m1-15-2-1-material (Catalog) material-id 12PC35482 issue-date 20120430

m1-15-2-1-1-clean-version

CATALOG 12PC35482 Product price catalog 20120430 [new]

±

-

Application Version =

Checksum = 49e150f4bee040a2de43c459affd6304

Checksum Type = md5

Filename = clean-catalog.pdf

Font Library =

ID = b21383b1861534dfd8a81df05237f704

Keywords =

Operation = new

Version =



# Non-2253 Grouped Submissions

- One cover letter should be placed under the appropriate cover letter heading
- Cover letter should include a list of all member Applications
  - Include Application Type & Number and Product Name
- It is not necessary to submit a Supplemental Application list if the cover letter lists all members of the group
- Subject line should reference the Lead Application Number and clearly identify the submission as a group

# Common Errors

# Batched Materials



- Submitting promotional materials for multiple products when the materials do not promote all members of the group
- Ex: Grouped 2253 contains 3 member Applications and 15 Promotional Materials
  - 5 Materials promote Product A, 5 Materials promote Product B, 5 Materials promote Product C
  - None of the Materials promote Products A, B, *and* C
- Promotional materials must promote all Products listed in the Group

# Application References



- Using Application References instead of Application Set
- Including one or multiple Applications in the References section of the US-Regional.xml file does not create a grouped submission
  - References only create a link between the Applications
  - References do not require or include a Sequence Number
- Including Application References will not distribute the submission to the Referenced Applications

# Example



<b>Application Information</b>	<p>Application Containing Files: true Application Type: New Drug Application (NDA) Application Number: 456789 Submission Type: Original Application Submission Id: 0001 Submission Sub-Type: Application Sequence #: 0003</p> <p>Cross Reference Number: 012345 Cross Reference Type: Drug Master File (DMF) Cross Reference Number: 543210 Cross Reference Type: Drug Master File (DMF)</p>
--------------------------------	--

# Missing Additional Applications

- Structuring a Single Product submission as a Grouped Submission
  - Submission includes all files required for a Grouped Submission
  - 2253 indicates Multi-Product submission
- US-Regional.xml file indicates submission is a single-product submission
- Submission will only be processed using the data included in the US-Regional file
- FDA cannot add Additional Applications that are not listed in the US-Regional.xml file even if the submission includes a Supplemental Application list

# Single Product Submissions



- Structuring a Grouped Submission as a Single Product Submission
  - Submission includes all files required for a Grouped Submission
  - 2253 indicates Multi-Product submission
- US-Regional.xml file indicates submission is a single-product submission
- Same submission is submitted multiple times
  - Submitter changes the Application Number listed in the US-Regional.xml file and submits individually
- Appears to be a grouped submission submitted separately to multiple Applications



# Test Submission Process



# Test Submissions



- Test Submission Process provides Submitters with an opportunity to validate eCTD submission structure prior to submitting to Production Environment
- OPDP Project Management Team will review the structure of the submission and provide feedback
  - Will provide instructions for corrections, if necessary

# Test Submissions - Process



- Begin by viewing the available presentations on the [OPDP eCTD webpage](#)
  - Prepare any questions you may have for the OPDP eCTD Team
- Contact the [OPDP eCTD Mailbox](#) and send the following items:
  - Questions to be answered
  - Types of Submissions (Accelerated Approval, Advisory, 2253, etc)
  - Availability (Dates & Times) for a 30-minute meeting
- OPDP eCTD Team will schedule a planning meeting
  - Will provide answers during the meeting
  - Assist with planning test cases
- Submit Test Files
  - Notify [OPDP eCTD Mailbox](#) of results (either accepted or rejected)
  - Be sure to provide the COR ID when the file is accepted
- OPDP eCTD Team will review test submission(s) and provide feedback



# Resources

- OPDP eCTD Mailbox- [OPDPeCTD@fda.hhs.gov](mailto:OPDPeCTD@fda.hhs.gov)
- OPDP eCTD Webpage - [www.fda.gov/OPDPeCTD](http://www.fda.gov/OPDPeCTD)
- eCTD Test Submission Instructions - <https://www.fda.gov/industry/create-esg-account/setting-webtrader-account-checklist>
- OPDP Electronic Submissions Guidance - <https://www.fda.gov/media/128163/download>
- eCTD Validation Criteria - <https://www.fda.gov/media/87056/download>
- Comprehensive Table of Headings – <https://www.fda.gov/media/76444/download>
- eCTD Submission Standards – <https://www.fda.gov/media/93301/download>
- eCTD Sample Submissions - <https://www.fda.gov/media/83809/download>

